Clinical trials
Completed Ocular Hypertension trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
483 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 7 |
| 2002 | 6 |
| 2003 | 13 |
| 2004 | 5 |
| 2005 | 22 |
| 2006 | 23 |
| 2007 | 24 |
| 2008 | 25 |
| 2009 | 34 |
| 2010 | 42 |
| 2011 | 45 |
| 2012 | 23 |
| 2013 | 30 |
| 2014 | 31 |
| 2015 | 15 |
| 2016 | 19 |
| 2017 | 12 |
| 2018 | 18 |
| 2019 | 17 |
| 2020 | 9 |
| 2021 | 13 |
| 2022 | 8 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 8 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 483 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alcon Research | 90 |
| Allergan | 72 |
| Aerie Pharmaceuticals | 22 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 22 |
| Santen Inc. | 12 |
| Santen Pharmaceutical Co., Ltd. | 12 |
| Mati Therapeutics Inc. | 11 |
| Glaukos Corporation | 10 |
| Bausch & Lomb Incorporated | 9 |
| ForSight Vision5, Inc. | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ocular Hypertension | 483 |
| Glaucoma, Open-Angle | 323 |
| Glaucoma | 237 |
| Eye Diseases | 17 |
| Hypertension | 16 |
| Exfoliation Syndrome | 8 |
| Cataract | 5 |
| Low Tension Glaucoma | 5 |
| Glaucoma, Angle-Closure | 4 |
| Diabetic Retinopathy | 3 |
Trials
Showing 51 to 75 of 483. Each trial links to its page on Pharma Observatory.
383 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.